US FDA Signals Increased Enforcement Activity against Prescription Drug Advertising and Promotion
This article was originally published in SRA
Executive Summary
The US Food and Drug Administration is increasingly issuing letters to companies alleging violations in promotional material for prescription drugs, say Gerald Masoudi and Stefanie Doebler.
You may also be interested in...
With US Respiratory Pipeline Unlocked, Cipla Wants Lung Leadership
Cipla sees an incremental revenue opportunity of up to $500m for its US franchise by fiscal 2025 and expects to propel growth with strong execution of its complex generics pipeline. The company is also beginning to “lay the blueprint” in China and Brazil, it said at the J.P. Morgan Healthcare Conference.
Teva CEO Schultz: ‘Proof Is In The Pudding’ For US Biosimilars
Teva CEO Kåre Schultz believes his prediction is coming true for the Truxima biosimilar in-licensed from Celltrion, as he gave the latest update on Teva’s efforts to settle significant legal issues around the US opioid crisis.
EU Notified Body Association Takes Steps To Allay EC’s Virtual Audit Fears
The European Commission has reluctantly allowed virtual audits in the context of new MDR and IVDR. The EU notified body association is helping the collective effort to meet its strict requirements.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: